Carlsmed Reports Strong Q1 2026 Earnings with 58% Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 05 2026
0mins
Source: Yahoo Finance
- Significant Revenue Growth: Carlsmed reported Q1 2026 revenue of $16.1 million, reflecting a 58% year-over-year increase, primarily driven by the expansion of its surgeon user base and increased procedure volumes, indicating a rapidly growing market demand for personalized surgery.
- Surgeon User Base Expansion: The company noted a more than 60% year-over-year increase in surgeon users, highlighting accelerated clinical adoption of personalized surgery procedures, particularly among early-career and post-fellowship surgeons, which further enhances market penetration.
- Improved Production Efficiency: Through technology investments, Carlsmed reduced lead times by over 30%, achieving delivery of surgical kits within six business days post-surgeon approval, and this capital-light, demand-driven model enables rapid scaling while maintaining a focus on patient outcomes.
- Strong Market Outlook: With the recent CMS proposal for 2027, all Aprivile lumbar fusion procedures will receive higher reimbursement, providing greater economic value to hospitals and further driving Carlsmed's growth potential in the spine surgery market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CARL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CARL
Wall Street analysts forecast CARL stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 12.570
Low
18.00
Averages
20.50
High
24.00
Current: 12.570
Low
18.00
Averages
20.50
High
24.00
About CARL
Carlsmed, Inc. is a commercial-stage medical technology company providing AI-enabled personalized spine surgery solutions. Its aprevo technology platform offers solutions for the entire surgical workflow, including pre-operative AI-enabled, surgical planning; intra-operative advanced visualization to support precision placement of aprevo interbody implants, and post-operative data collection and insights for each surgeon. Its pre-operative planning software utilizes standard-of-care diagnostic imaging and AI-enabled algorithms to develop personalized digital surgical plans and to design aprevo interbody implants for each patient's pathology and vertebral bone topography. Additionally, the aprevo technology platform supports the collection of real-world, post-operative data to inform its digital surgical planning process. Its platform is commercially available in the United States and is indicated for use in lumbar interbody fusion procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Latest Wall Street Rating Updates
- Abbott Labs Upgrade: Baird initiates coverage on Abbott Labs (ABT) with an outperform rating, projecting steady revenue and earnings growth of 6-8% over the next few years, bolstered by its leading position in the rapidly growing MedDevice market, enhancing the company's competitive edge.
- Murphy USA Upgrade: Jefferies upgrades Murphy USA (MUSA) from hold to buy, citing improving fuel margins that are expected to drive EBITDA outlook significantly higher by 20-25%, which will materially enhance the company's financial performance in the coming years.
- Abivax Upgrade: Jefferies raises Abivax (ABVX) to buy, noting strong data for its ulcerative colitis drug that alleviates key market concerns, which is likely to drive a rebound in the stock price.
- Talos Energy Upgrade: Roth upgrades Talos Energy (TALO) from neutral to buy, raising the price target by 6% to $17, based on its robust balance sheet and low production decline rates, indicating strong future growth potential.
See More
Carlsmed Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: Carlsmed reported Q1 2026 revenue of $16.1 million, representing a 58% year-over-year increase, indicating strong market demand and product acceptance that is expected to drive future revenue growth.
- Operational Efficiency Improvement: By leveraging technology investments, Carlsmed reduced production lead times by over 30% to 6 business days, resulting in 200 basis points of margin expansion, showcasing the company's ongoing improvements in operational efficiency.
- User Base Expansion: The total surgeon user base grew by over 60% year-over-year, indicating increasing acceptance of the aprevo lumbar fusion procedure in the U.S. market, which is expected to further drive market share growth.
- Optimistic Outlook: Carlsmed raised its 2026 revenue guidance to between $72 million and $77 million, reflecting a 48% growth at the midpoint, which demonstrates the company's confidence in new product launches and market expansion.
See More
Carlsmed Reports Q1 Earnings with Revenue of $16.1M
- Earnings Performance: Carlsmed, Inc. reported a Q1 GAAP EPS of -$0.32, indicating challenges in profitability, although revenue reached $16.1 million, reflecting ongoing market demand.
- Revenue Growth Target: The company aims for 2026 revenue between $70 million and $75 million, demonstrating management's confidence in future product launches, particularly in the cervical and bilateral product markets.
- Growth Outlook: Carlsmed anticipates a 44% growth rate moving forward, showcasing strong momentum in the medical device sector, especially post-launch of new products that could attract more customers.
- Historical Financial Data: Despite the current quarter's underperformance, the historical financial data provides investors with context to assess the company's long-term growth potential and market positioning.
See More
Carlsmed (CARL) Q1 2026 Earnings Transcript
See More
Carlsmed Reports Strong Q1 2026 Earnings with 58% Revenue Growth
- Significant Revenue Growth: Carlsmed reported Q1 2026 revenue of $16.1 million, reflecting a 58% year-over-year increase, primarily driven by the expansion of its surgeon user base and increased procedure volumes, indicating a rapidly growing market demand for personalized surgery.
- Surgeon User Base Expansion: The company noted a more than 60% year-over-year increase in surgeon users, highlighting accelerated clinical adoption of personalized surgery procedures, particularly among early-career and post-fellowship surgeons, which further enhances market penetration.
- Improved Production Efficiency: Through technology investments, Carlsmed reduced lead times by over 30%, achieving delivery of surgical kits within six business days post-surgeon approval, and this capital-light, demand-driven model enables rapid scaling while maintaining a focus on patient outcomes.
- Strong Market Outlook: With the recent CMS proposal for 2027, all Aprivile lumbar fusion procedures will receive higher reimbursement, providing greater economic value to hospitals and further driving Carlsmed's growth potential in the spine surgery market.
See More
Carlsmed Reports Q4 Earnings Beat with Strong Revenue Growth Outlook
- Earnings Beat: Carlsmed reported a Q4 GAAP EPS of -$0.32, surpassing expectations by $0.11, indicating positive progress in the company's recovery of profitability.
- Revenue Growth: The company achieved Q4 revenue of $15.2 million, exceeding market expectations by $0.34 million, reflecting strong product demand and an increase in market share.
- Future Outlook: Carlsmed targets revenue between $70 million and $75 million for 2026, with plans to launch cervical and bilateral products, demonstrating confidence in future growth.
- Growth Prospects: The company anticipates a 44% growth outlook, highlighting its competitiveness and ongoing innovation capabilities in the medical device market.
See More
Latest Wall Street Rating Updates
- Abbott Labs Upgrade: Baird initiates coverage on Abbott Labs (ABT) with an outperform rating, projecting steady revenue and earnings growth of 6-8% over the next few years, bolstered by its leading position in the rapidly growing MedDevice market, enhancing the company's competitive edge.
- Murphy USA Upgrade: Jefferies upgrades Murphy USA (MUSA) from hold to buy, citing improving fuel margins that are expected to drive EBITDA outlook significantly higher by 20-25%, which will materially enhance the company's financial performance in the coming years.
- Abivax Upgrade: Jefferies raises Abivax (ABVX) to buy, noting strong data for its ulcerative colitis drug that alleviates key market concerns, which is likely to drive a rebound in the stock price.
- Talos Energy Upgrade: Roth upgrades Talos Energy (TALO) from neutral to buy, raising the price target by 6% to $17, based on its robust balance sheet and low production decline rates, indicating strong future growth potential.
See More
Carlsmed Reports Strong Q1 2026 Earnings Growth
- Significant Revenue Growth: Carlsmed reported Q1 2026 revenue of $16.1 million, representing a 58% year-over-year increase, indicating strong market demand and product acceptance that is expected to drive future revenue growth.
- Operational Efficiency Improvement: By leveraging technology investments, Carlsmed reduced production lead times by over 30% to 6 business days, resulting in 200 basis points of margin expansion, showcasing the company's ongoing improvements in operational efficiency.
- User Base Expansion: The total surgeon user base grew by over 60% year-over-year, indicating increasing acceptance of the aprevo lumbar fusion procedure in the U.S. market, which is expected to further drive market share growth.
- Optimistic Outlook: Carlsmed raised its 2026 revenue guidance to between $72 million and $77 million, reflecting a 48% growth at the midpoint, which demonstrates the company's confidence in new product launches and market expansion.
See More
Carlsmed Reports Q1 Earnings with Revenue of $16.1M
- Earnings Performance: Carlsmed, Inc. reported a Q1 GAAP EPS of -$0.32, indicating challenges in profitability, although revenue reached $16.1 million, reflecting ongoing market demand.
- Revenue Growth Target: The company aims for 2026 revenue between $70 million and $75 million, demonstrating management's confidence in future product launches, particularly in the cervical and bilateral product markets.
- Growth Outlook: Carlsmed anticipates a 44% growth rate moving forward, showcasing strong momentum in the medical device sector, especially post-launch of new products that could attract more customers.
- Historical Financial Data: Despite the current quarter's underperformance, the historical financial data provides investors with context to assess the company's long-term growth potential and market positioning.
See More
Carlsmed (CARL) Q1 2026 Earnings Transcript
See More
Carlsmed Reports Strong Q1 2026 Earnings with 58% Revenue Growth
- Significant Revenue Growth: Carlsmed reported Q1 2026 revenue of $16.1 million, reflecting a 58% year-over-year increase, primarily driven by the expansion of its surgeon user base and increased procedure volumes, indicating a rapidly growing market demand for personalized surgery.
- Surgeon User Base Expansion: The company noted a more than 60% year-over-year increase in surgeon users, highlighting accelerated clinical adoption of personalized surgery procedures, particularly among early-career and post-fellowship surgeons, which further enhances market penetration.
- Improved Production Efficiency: Through technology investments, Carlsmed reduced lead times by over 30%, achieving delivery of surgical kits within six business days post-surgeon approval, and this capital-light, demand-driven model enables rapid scaling while maintaining a focus on patient outcomes.
- Strong Market Outlook: With the recent CMS proposal for 2027, all Aprivile lumbar fusion procedures will receive higher reimbursement, providing greater economic value to hospitals and further driving Carlsmed's growth potential in the spine surgery market.
See More
Carlsmed Reports Q4 Earnings Beat with Strong Revenue Growth Outlook
- Earnings Beat: Carlsmed reported a Q4 GAAP EPS of -$0.32, surpassing expectations by $0.11, indicating positive progress in the company's recovery of profitability.
- Revenue Growth: The company achieved Q4 revenue of $15.2 million, exceeding market expectations by $0.34 million, reflecting strong product demand and an increase in market share.
- Future Outlook: Carlsmed targets revenue between $70 million and $75 million for 2026, with plans to launch cervical and bilateral products, demonstrating confidence in future growth.
- Growth Prospects: The company anticipates a 44% growth outlook, highlighting its competitiveness and ongoing innovation capabilities in the medical device market.
See More
